| Literature DB >> 36158563 |
Yi Zhang1, Meng Zhang1.
Abstract
Pharmacological studies have shown that some traditional Chinese medicines (TCMs) have applications in the treatment of Alzheimer's disease (AD). Morinda officinalis How. (MO) is a TCM with a long history and is widely used to tonify kidney Yang. In vitro and in vivo experiments have suggested that MO contains various effective pharmaceutical components and chemicals, including oligosaccharides, anthraquinones, iridoids, flavonoids, amino acids, and trace elements, conferring MO with anti-inflammatory and antioxidant properties. Neuroinflammation and oxidative stress are undoubtedly hallmarks of neurodegeneration, contributing to AD progression. In this mini-review, we summarize the molecular mechanisms, structure-activity relationships, and potential synergistic and antagonistic effects of active components in MO. This discussion highlights the roles of these active components, such as oligosaccharides, anthraquinones, and iridoid glycosides, in the treatment of AD via anti-inflammatory and antioxidant mechanisms, providing a scientific basis for further utilization of MO.Entities:
Keywords: Alzheimer’s disease; Morinda officinalis How.; antioxidative; neuroinflammation; neuroprotection
Year: 2022 PMID: 36158563 PMCID: PMC9493036 DOI: 10.3389/fnagi.2022.963041
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.702
FIGURE 1The structures of the main polysaccharides (MP-1, MP-2, MP-3) in Morinda officinalis How.
FIGURE 2The structures of the main iridoids in Morinda officinalis How.
Pharmacological activities of M. officinalis How. in AD treatment.
| Tested substance | Models | Tested living system/cell | Results | Dose range | Application time | Main anti-AD mechanism | References |
|
| APP/PS1 mice | Mice | Suppress the neuroinflammatory response, increase expression of neurotrophic factors | 80 mg/kg/d | 4 weeks | Inhibit neuroinflammation |
|
| OMO | D-Galactose/Aβ25–35 induced rat model | Rats | Alleviate oxidative damage, increase neurotransmitter levels and relative synaptophysin expression | 480 mg/kg/d | 4 weeks | Anti-oxidant effects |
|
| OMO | Aβ25–35 induced rats | Rats | Enhance oxidation resistance, activate brain energy metabolism and improve the injury of cholinergic system. | 60 mg/kg/d | 25 days | Enhance oxidation resistance |
|
|
| Aβ25–35 induced cell | Pheochromocy | Reverse the reduction in cell viability, blockade of mitochondria-dependent apoptosis. | 40 μM | 2 h | Against oxidative stress |
|
|
| APP/PS1 mice | Mice | Reduced ROS and MDA levels, and alleviate endoplasmic reticulum stress. | 70 mg/kg/d | 4 weeks | Alleviate oxidative stress |
|
|
| Aβ25–35 induced rats | Rats | Enhance antioxidative activity and energy metabolism, and attenuate cholinergic system damage | 2 g/kg/d | 2 weeks | Inhibit oxidative stress |
|
| OMO | APP/PS1 transgenic/C57BL/6J male mice | Mice | Improve in the gut microbiome and metabolome | 100 mg/kg/d | 4 weeks | Regulate the key microbiota-metabolite pairs |
|
| FOS | D-Galactose/Aβ25–35 induced rat model | Rats | Alter the gut structure of the microbiota, promote the engraftment ability of Bifidobacterium | 100 mg/kg/d | 28 days | Alter the diversity and stability of the microbial community |
|
AD, Alzheimer’s disease; OMO, oligosaccharides of Morinda officinalis How.; FOS, fructose-oligosaccharides.
FIGURE 3Antioxidative and Anti-inflammatory activities of Morinda officinalis How. (MO) and its main components. MO may be used to treat Alzheimer’s disease and improve functional behavioral outcomes by reducing oxidative stress, inhibiting inflammatory factors, enhancing the intestinal microbiome and metabolome, and increasing neurotransmitter and neurotrophic factor expression. 5-HT, 5-hydroxytryptamine; BDNF, brain-derived neurotrophic factor; DA, dopamine; IL-1β, interleukin-1β; MDA, malondialdehyde; NE, norepinephrine; NF-κB, nuclear factor kappa-B; ROS, reactive oxygen species; TNF-α, tumor necrosis factor α.